Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene
NCT ID: NCT01962129
Last Updated: 2013-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
133 participants
OBSERVATIONAL
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Identification of the molecular bases of the different OFD syndromes will make it possible to determine whether or not they belong to the group of ciliopathies like type I OFD and to understand their physiopathological bases.
This study will also make it possible to better characterise the phenotype of boys with syndromic mental retardation related to the OFD1 gene and thus to define the clinical criteria of the study of this gene in boys with mental retardation.
The complete absence of knowledge concerning the genetic bases of OFD syndromes, apart from type I, the presence of a large collection of samples from patients with OFD syndrome at Dijon CHU, the recognition of the diagnostic laboratory for syndromic OFD at the international level as well as the technical platform and expertise in molecular cytogenetic methods including CGH-array and molecular genetics (sequencing, quantitative PCR, fragment analysis) at the Cytogenetics and Molecular Biology laboratories at Dijon CHU justify the implementation of such a study in 2010.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients affected by a syndrome OFD
Sampling of blood
Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE
Sampling of blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sampling of blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The clinical data are already available from Doctor Christel Thauvin-Robinet, who is responsible for this collection. These patients have signed a non-opposition form allowing the use of their blood samples for research on OFD syndromes. These patients will therefore be included in this new study without the need for new consent. Only an information letter will be sent to them (annexe 4A)
Patients will be recruited by the clinical investigators of this study. These patients could be:
* patients already known by the investigator, who will contact the patient to invite them to take part in the research,
* or new patients seen during a consultation in the first year of the study (inclusion period) The clinical dossier that accompanies each sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form Symptomatic and asymptomatic relatives may also be included in our study, once their written informed consent has been provided, so as to exclude polymorphism using CGH-array or molecular biology, or to confirm the segregation of a mutation.
Minors will only be included in our study if they are symptomatic. All of those who take part in this research, whether they are patients or healthy or asymptomatic relatives have to be covered by a national health insurance agency.
Group 2: Study of the form of syndromic X-linked mental retardation secondary to mutations in the OFD1 gene Preexisting patient cohorts
Two different types of populations could be included:
* Boys with Joubert syndrome with cerebellar hypoplasia at the origin of the "molar tooth" sign on cerebral MRI and a negative result for mutations in the genes involved in Joubert syndrome as described by Doctor Burglen (Hospital Trousseau, APHP)
* Boys with a phenotype that could be linked to mutations in the OFD1 gene:
* A cohort of boys with polydactyly+/- juvenile retinitis pigmentosa or obesity who were screened negative for BBS gene mutations recruited through Professor Dollfus (CHU Strasbourg)
* A cohort of males with severe macrocephaly (\>+4SD) with negative screening for mutations in the GPC3 gene recruited through Doctor Rossignol (CHU Trousseau, Paris) and Doctor Raynaud (CHU Tours).
* A cohort of males with recurrent pulmonary infections, macrocephaly (\>+4SD) and negative screening for mutations in the MECP2 gene recruited through Doctor Philippe (CHU Nancy), Doctor Badens (CHU Marseille), Professor Bieth (CHU Toulouse) and Professor Touraine (CHU St Etienne).
The clinical dossier that accompanies each DNA sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form
Patients will be recruited by the clinical investigators of this study. These patients could be:
* patients already known by the investigator, who will contact the patient to invite them to take part in the research,
* or new patients seen during a consultation in the first year of the study (inclusion period) The clinical dossier that accompanies each sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form Symptomatic and asymptomatic relatives may also be included in our study, once their written informed consent has been provided, so as to exclude polymorphism using CGH-array or molecular biology, or to confirm the segregation of a mutation.
Minors will only be included in our study if they are symptomatic. All of those who take part in this research, whether they are patients or healthy or asymptomatic relatives have to be covered by a national health insurance agency.
Exclusion Criteria
Patients with OFD syndrome in whom sequencing of the exons or exon-intron junctions of the OFD1 gene of genomic DNA and the search for major rearrangements quantitative PCR identify a causal mutation will not be included in this study.
The following patients will also be excluded from the study:
* those who do not wish to provide a blood sample,
* those who have not provided written informed consent,
* those without national health insurance,
* those in custody following a legal or administrative decision.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christel Thauvin
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Thauvin PHRC N 2010
Identifier Type: -
Identifier Source: org_study_id